Allergy Therapeutics (LSE:AGY) ended a bruising few years on a firmer footing. In a trading update released on 29 July 2026, the Worthing-based allergy specialist told the market that revenue for the year to 30 June 2026 is expected to reach roughly £59.9m, up …
Faron Pharmaceuticals (LSE:FARN), the Finnish clinical-stage immuno-oncology company dual-listed on London's AIM and Nasdaq First North Growth Market in Helsinki, has given investors their first look at survival outcomes from its lead programme in a hard-to-treat blood cancer. On 27 July 2026 the company …
Faron Pharmaceuticals (LSE:FARN), the Finnish clinical-stage immuno-oncology company dual-listed on London's AIM and Nasdaq First North Growth Market in Helsinki, has given investors their first look at survival outcomes from its lead programme in a hard-to-treat blood cancer. On 27 July 2026 the company …
EKF Diagnostics (LSE:EKF) gave investors a familiar message on 30 July 2026, but with a sharper edge on profitability. In an unaudited trading update covering the six months to 30 June 2026, the AIM-listed diagnostics and life sciences group reported that revenue held broadly …
Shares ofLSE:POLBclosed approximately4.35% loweron6 August 2026, attracting investor attention after recording one of the larger declines among UK-listed biotechnology companies.
Arecor Therapeutics (LSE:AREC) enters the second half of 2026 at an inflection point. The Cambridge-based, AIM-quoted formulation specialist has spent the past year reshaping itself into a leaner, cash-metabolic business built around two assets designed to make diabetes and obesity treatment less onerous for …
Shares in Abingdon Health (LSE:ABDX), the York-based lateral flow diagnostics group, moved into focus at the end of July after the company told investors that unaudited revenue for the year to 30 June 2026 had climbed 31% to around £11.3m, and, more significantly for …
Shield Therapeutics (LSE:STX), the AIM-quoted specialty pharmaceutical company behind the oral iron therapy Accrufer, delivered a headline-grabbing set of interim numbers on 30 July 2026, reporting first-half revenue of $30.4m and reaffirming that it remains on track to turn profitable across the full year. …
Creo Medical (LSE:CREO) opened its interim results on 28 July 2026 with the sort of headline number that tends to concentrate investor minds: first-half revenue up 45% to £3.2m. Yet the more telling part of the update sat beneath the top line. The Welsh …
Poolbeg Pharma (LSE:POLB) has topped up its balance sheet at a moment when its investment case is about to be tested in the clinic. The AIM-quoted biotech confirmed on 14 July 2026 that it had raised £3.5m gross through a placing of 58,333,328 new …